MX2015014171A - Uso de 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas. - Google Patents
Uso de 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas.Info
- Publication number
- MX2015014171A MX2015014171A MX2015014171A MX2015014171A MX2015014171A MX 2015014171 A MX2015014171 A MX 2015014171A MX 2015014171 A MX2015014171 A MX 2015014171A MX 2015014171 A MX2015014171 A MX 2015014171A MX 2015014171 A MX2015014171 A MX 2015014171A
- Authority
- MX
- Mexico
- Prior art keywords
- lymphoma
- compound
- cell lymphoma
- nhl
- hodgkin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención está relacionada con los siguientes aspectos. - El uso de un compuesto del tipo de las 2,3-dihidroimidazo[1,2-c]quinazolinas, o de una composición farmacéutica que lo contiene, como único agente activo, o de una combinación de (a) el compuesto que se ha descripto o una composición farmacéutica que lo contiene y (b) uno o más agentes activos adicionales en la elaboración de un medicamento útil para tratar o prevenir un linfoma no Hodgkin (NHL), particularmente un linfoma no Hodgkin (NHL) de la primera línea, de la segunda línea, recurrente, refractario, indolente o agresivo, más particularmente un linfoma folicular (FL), una leucemia linfocítica crónica (LLC), un linfoma en una zona marginal (MZL), un linfoma difuso en las células B (DLBCL), un linfoma en las células del manto (MCL), un linfoma transformado (TL) o un linfoma en las células T periféricas (PTCL). - Una combinación que comprende (a) el compuesto que se ha descripto y (b) uno o más agentes activos adicionales. - Una composición farmacéutica que comprende el compuesto que se ha descripto como único agente activo y que resulta útil para tratar un linfoma no Hodgkin (NHL), particularmente un linfoma no Hodgkin (NHL) de la primera línea, de la segunda línea, recurrente, refractario, indolente o agresivo, más particularmente un linfoma folicular (FL), una leucemia linfocítica crónica (LLC), un linfoma en una zona marginal (MZL), un linfoma difuso en las células B (DLBCL), un linfoma en las células del manto (MCL), un linfoma transformado (TL) o un linfoma en las células T periféricas (PTCL). - Una composición farmacéutica que está compuesta por una combinación que comprende (a) el compuesto que se ha descripto y (b) uno o más agentes activos adicionales. - El uso de indicadores biológicos como la expresión de las isoformas de las PI3K, la activación de las BTK, de las IKK o de los BCR, la activación de los BCR más allá de la vía del NF?B, c-Myc o EZH2 para predecir la sensibilidad y/o la resistencia de un paciente que padece un cáncer al compuesto que se ha descripto y para proveer una combinación sinérgica con un fundamento racional que es como se la define en la presente, que resulte útil para incrementar la sensibilidad y/o para superar la resistencia. - Un método para determinar el nivel de uno o más de los siguientes componentes: la expresión de las isoformas de las PI3K, la activación de las BTK, de las IKK o de los BCR, la activación de los BCR más allá de la vía del NF?B, c-Myc o EZH2.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13162710 | 2013-04-08 | ||
| EP13184240 | 2013-09-13 | ||
| PCT/EP2014/056768 WO2014166820A1 (en) | 2013-04-08 | 2014-04-04 | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015014171A true MX2015014171A (es) | 2015-12-16 |
Family
ID=50439383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015014171A MX2015014171A (es) | 2013-04-08 | 2014-04-04 | Uso de 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas. |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US9999623B2 (es) |
| EP (1) | EP2983669B1 (es) |
| JP (1) | JP6368353B2 (es) |
| KR (1) | KR102304108B1 (es) |
| CN (1) | CN105263497B (es) |
| AP (1) | AP2015008750A0 (es) |
| AU (1) | AU2014253348B2 (es) |
| BR (1) | BR112015025304B1 (es) |
| CA (1) | CA2908776C (es) |
| CL (1) | CL2015002978A1 (es) |
| CR (1) | CR20150523A (es) |
| CU (1) | CU24400B1 (es) |
| DO (1) | DOP2015000256A (es) |
| EA (2) | EA031493B9 (es) |
| ES (1) | ES2708350T3 (es) |
| IL (1) | IL241543B (es) |
| JO (1) | JOP20140141B1 (es) |
| MX (1) | MX2015014171A (es) |
| MY (1) | MY192626A (es) |
| NI (1) | NI201500148A (es) |
| PE (1) | PE20151780A1 (es) |
| PH (1) | PH12015502317A1 (es) |
| SG (2) | SG11201507265XA (es) |
| TN (1) | TN2015000452A1 (es) |
| TW (2) | TWI675663B (es) |
| UA (2) | UA122822C2 (es) |
| WO (1) | WO2014166820A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2168583A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
| EP2508525A1 (en) * | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| EP3077003A1 (en) | 2013-12-03 | 2016-10-12 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
| WO2015082376A2 (en) * | 2013-12-03 | 2015-06-11 | Bayer Pharma Aktiengesellschaft | Use of pi3k-inhibitors |
| CN105017256A (zh) | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| EP3018127A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| WO2016087490A1 (en) * | 2014-12-03 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
| WO2016087488A1 (en) * | 2014-12-03 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Administration regime for aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives |
| JP6867295B2 (ja) | 2015-03-09 | 2021-04-28 | バイエル ファーマ アクチエンゲゼルシャフト | 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリンを含んでいる組合せ |
| US9717745B2 (en) | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
| PL3954690T3 (pl) | 2015-07-02 | 2023-08-14 | Acerta Pharma B.V. | Postacie stałe i formulacje (s)-4-(8-amino-3-(1-(but-2-ynoilo)pirolidyn-2-ylo)imidazo[1,5-a]-pirazyn-1-ylo)-n-(pirydyn-2-ylo)benzamidu |
| AU2017215096A1 (en) * | 2016-02-01 | 2018-08-09 | Bayer Pharma Aktiengesellschaft | Copanlisib biomarkers |
| MX2018009368A (es) * | 2016-02-01 | 2018-09-05 | Bayer Pharma AG | Biomarcadores para copanlisib. |
| CA3016584A1 (en) | 2016-03-08 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | 2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides |
| EP3219329A1 (en) * | 2016-03-17 | 2017-09-20 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib |
| WO2017221092A1 (en) * | 2016-06-20 | 2017-12-28 | Novartis Ag | Triazolopyridine compounds and uses thereof |
| WO2017221100A1 (en) * | 2016-06-20 | 2017-12-28 | Novartis Ag | Imidazopyrimidine compounds useful for the treatment of cancer |
| CN109729716B (zh) | 2016-09-23 | 2022-03-15 | 拜耳制药股份公司 | Pi3k-抑制剂的组合产品 |
| MX393601B (es) * | 2017-05-18 | 2025-03-21 | Jiangsu Hengrui Medicine Co | Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores. |
| EP3645005A1 (en) | 2017-06-28 | 2020-05-06 | Bayer Consumer Care AG | Combination of a pi3k-inhibitor with an androgen receptor antagonist |
| BR112020005105A2 (pt) * | 2017-09-13 | 2020-09-15 | Guangdong Oppo Mobile Telecommunications Corp., Ltd. | método de processamento de dados e dispositivo terminal |
| TW201922256A (zh) | 2017-10-27 | 2019-06-16 | 中國大陸商浙江導明醫藥科技有限公司 | 治療淋巴樣惡性疾病之方法 |
| CA3157789A1 (en) * | 2019-10-15 | 2021-04-22 | Bayer Aktiengesellschaft | 2-methyl-aza-quinazolines |
| WO2022199373A1 (zh) * | 2021-03-26 | 2022-09-29 | 上海璎黎药业有限公司 | 一种喹唑啉化合物及药物组合物的应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1400959A (en) | 1919-04-26 | 1921-12-20 | Ste Chim Usines Rhone | Process and apparatus for carrying out chemical reactions by catalysis |
| US1364099A (en) | 1919-09-10 | 1921-01-04 | Flannery Bolt Co | Staybolt structure for boilers |
| US1400975A (en) | 1920-10-11 | 1921-12-20 | Page Henry Benjiman | Dirigible headlight for motor-vehicles |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| JP2003277383A (ja) * | 2002-03-14 | 2003-10-02 | Bayer Ag | 光学活性ピリジン誘導体およびそれを含む医薬 |
| UA82205C2 (en) | 2002-09-30 | 2008-03-25 | Байер Фармасьютикалз Корпорейшн | Fused azole-pyrimidine derivatives |
| AR064106A1 (es) * | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
| CA2713388C (en) | 2008-01-14 | 2016-03-29 | William Scott | Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| EP2168583A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
| PH12012502069A1 (en) | 2010-04-16 | 2013-02-04 | Bayer Ip Gmbh | Substituted 2,3-dihydroimidazo [1,2-c] quinazoline - containing combinations |
| CN102893688B (zh) | 2010-05-14 | 2016-03-09 | Lg电子株式会社 | 在无线通信系统中分配资源的方法及其装置 |
| UA113280C2 (xx) * | 2010-11-11 | 2017-01-10 | АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ | |
| JP5790016B2 (ja) | 2011-02-18 | 2015-10-07 | コベルコ建機株式会社 | ハイブリッド建設機械 |
| WO2012118632A1 (en) * | 2011-02-28 | 2012-09-07 | Ning Xi | Substituted quinoline compounds and methods of use |
| US20140213630A1 (en) * | 2011-03-08 | 2014-07-31 | Thomas Diacovo | Methods and pharmaceutical compositions for treating lymphoid malignancy |
| JO3733B1 (ar) | 2011-04-05 | 2021-01-31 | Bayer Ip Gmbh | استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة |
| EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| US10465247B2 (en) * | 2011-07-01 | 2019-11-05 | Dana-Farber Cancer Institute, Inc. | Discovery of a somatic mutation in MYD88 gene in lymphoplasmacytic lymphoma |
| US20150141470A1 (en) | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| US8993891B2 (en) | 2012-06-28 | 2015-03-31 | Thomas & Betts International, Inc. | Lift and pivot grommet |
| WO2015082322A1 (en) | 2013-12-03 | 2015-06-11 | Bayer Pharma Aktiengesellschaft | COMBINATION of PI3K-INHIBITORS |
| EP3018127A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| EP3018131A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| AU2016231260A1 (en) | 2015-03-09 | 2017-09-21 | Bayer Healthcare Pharmaceuticals Inc. | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
| JP6867295B2 (ja) | 2015-03-09 | 2021-04-28 | バイエル ファーマ アクチエンゲゼルシャフト | 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリンを含んでいる組合せ |
-
2014
- 2014-04-04 MX MX2015014171A patent/MX2015014171A/es unknown
- 2014-04-04 SG SG11201507265XA patent/SG11201507265XA/en unknown
- 2014-04-04 JP JP2016505835A patent/JP6368353B2/ja not_active Expired - Fee Related
- 2014-04-04 TN TN2015000452A patent/TN2015000452A1/en unknown
- 2014-04-04 WO PCT/EP2014/056768 patent/WO2014166820A1/en not_active Ceased
- 2014-04-04 CN CN201480032696.4A patent/CN105263497B/zh not_active Expired - Fee Related
- 2014-04-04 CA CA2908776A patent/CA2908776C/en active Active
- 2014-04-04 UA UAA201812437A patent/UA122822C2/uk unknown
- 2014-04-04 EP EP14715293.8A patent/EP2983669B1/en active Active
- 2014-04-04 CU CU2015000140A patent/CU24400B1/es unknown
- 2014-04-04 PE PE2015002123A patent/PE20151780A1/es unknown
- 2014-04-04 BR BR112015025304-0A patent/BR112015025304B1/pt not_active IP Right Cessation
- 2014-04-04 UA UAA201510750A patent/UA119537C2/uk unknown
- 2014-04-04 MY MYPI2015703538A patent/MY192626A/en unknown
- 2014-04-04 EA EA201591932A patent/EA031493B9/ru not_active IP Right Cessation
- 2014-04-04 AP AP2015008750A patent/AP2015008750A0/xx unknown
- 2014-04-04 SG SG10201710539QA patent/SG10201710539QA/en unknown
- 2014-04-04 ES ES14715293T patent/ES2708350T3/es active Active
- 2014-04-04 US US14/781,224 patent/US9999623B2/en active Active
- 2014-04-04 EA EA201792650A patent/EA037577B1/ru unknown
- 2014-04-04 KR KR1020157031640A patent/KR102304108B1/ko not_active Expired - Fee Related
- 2014-04-04 AU AU2014253348A patent/AU2014253348B2/en not_active Ceased
- 2014-04-06 JO JOP/2014/0141A patent/JOP20140141B1/ar active
- 2014-04-08 TW TW103112877A patent/TWI675663B/zh not_active IP Right Cessation
- 2014-04-08 TW TW107134848A patent/TWI689307B/zh not_active IP Right Cessation
-
2015
- 2015-09-10 IL IL241543A patent/IL241543B/en active IP Right Grant
- 2015-10-06 PH PH12015502317A patent/PH12015502317A1/en unknown
- 2015-10-07 CL CL2015002978A patent/CL2015002978A1/es unknown
- 2015-10-08 DO DO2015000256A patent/DOP2015000256A/es unknown
- 2015-10-08 NI NI201500148A patent/NI201500148A/es unknown
- 2015-10-08 CR CR20150523A patent/CR20150523A/es unknown
-
2018
- 2018-01-03 US US15/861,555 patent/US10226469B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502317A1 (en) | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas | |
| TN2013000402A1 (en) | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines | |
| NZ772688A (en) | The use of inhibitors of bruton’s tyrosine kinase (btk) | |
| SG10201811128RA (en) | Ezh2 inhibitors for treating lymphoma | |
| MX2009009304A (es) | Inhibidores de cinasa pim y metodos para su uso. | |
| TN2010000208A1 (en) | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents | |
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| EA201100425A1 (ru) | Производные пиколинамида в качестве ингибиторов киназы | |
| NZ609201A (en) | Means and methods for treating dlbcl | |
| MY183661A (en) | Treatment of cancer with tor kinase inhibitors | |
| AU2018341571A8 (en) | Therapeutic methods relating to HSP90 inhibitors | |
| MX2014002967A (es) | Antagonistas de los productos del agrupamiento de unigenes hs.459642 para la inhibicion de la proliferacion, del desarrollo o de la diferenciacion de las celulas madre incluyendo las celulas madre cancerosas. | |
| MX2013010770A (es) | Tratamiento de tumores solidos. | |
| CL2011001445A1 (es) | Compuesto 3-(4-cloro-2-fluorobencil)-2-metil-n-(5-metil-1h-pirazol-3-il)-8-(morfolinometil)imidazo[1,2-b]piridazin-6-amina; composicion farmaceutica; y uso en el tratamiento de trastornos mieloproliferantes cronicos y en el tratamiento de glioblastoma, cancer de amama, mieloma multiple, cancer de prostata y leucemias | |
| AR056801A1 (es) | Terapia combinada anti- proliferativa con determinados agentes quimioterapeuticos basados en platino e inhibidores de egfr o analogos de pirimidina | |
| UY33740A (es) | Método para tratar el cáncer de mama y cáncer de ovarios | |
| CL2009000986A1 (es) | Uso de inhibidores de pai-1 para la p0reparacion de un medicamento util en el tratamiento de hipertension ocular y glaucoma | |
| Macauley et al. | American Association for Cancer Research (AACR)-103rd Annual Meeting, Chicago, Illinois, USA-March 31-April 4, 2012 | |
| UA99934C2 (ru) | Лечение рака молочной железы с помощью соединения 4-йодо-3-нитробензамида в комбинации с противоопухолевыми средствами | |
| JO3055B1 (ar) | مشتقات بيكوليناميد كمثبطلت كيناز | |
| TN2011000070A1 (en) | Picolinamide derivatives as kinase inhibitors | |
| DOP2005000197A (es) | Method for treting vasculitis |